Citations

Clear

3138 citation(s) found for "Smith, AM".

Arthroscopic Congruent‐Arc Distal Tibial Allograft Bone Augmentation With Cerclage Fixation for Anterior Shoulder Instability With Bone Loss
Hoffer, Alexander J , Lai, Cara , Smith, Casandra , Tokish, John M., Lai, Cara H , Tummala, Sailesh V , Tummala, Sailesh V.

Mayo Clinic

Arthroscopy Techniques | November 29, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1016/j.eats.2024.103344 | PMID 40452999 Get It

Abstract Glenoid bone loss is a common sequela of recurrent anterior shoulder instability. When treated surgically, a bone augmentation procedure is more likely to provide a good outcome with a lower risk of recurrent instability compared with a soft‐tissue repair alone. There are several bone augmentation options to address glenoid bone loss, including coracoid transfer, iliac crest autograft, and distal tibial allograft (DTA). Both open and arthroscopic DTA techniques have been described using the lateral one‐third of the distal tibia oriented with the anterior aspect placed superiorly on the anterior glenoid. This graft orientation places its concavity in the superior‐to‐inferior direction. It may be preferred to have this concavity maximized toward the anterior direction so that it can further resist anterior displacement. The posterior one‐third of the distal tibia may provide a more optimal arc of resistance. However, no previous technique has used the posterior one‐third of the distal tibia to reconstruct the “half‐pipe” concavity of the anterior glenoid. We describe an all‐arthroscopic technique for a posterior third DTA oriented with the posterior tibial edge placed anteriorly on the glenoid, termed the “congruent‐arc DTA,” to address anterior shoulder instability with bone loss. Technique Video video See video under supplementary data.
Human Research Protections Basics for New Investigators
Siapno, Rochelle, Smith, Laura , Throne, Robin , Siapno, Rochelle

Mayo Clinic

Advances in Data Mining and Database Management | November 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-20

10.4018/979-8-3693-3848-3.ch001 Get It

This chapter introduces human subjects research protections basics from a United States regulatory perspective. An introduction to the institutional review board (IRB) office provides descriptions of the types of research activities considered human subjects research (HSR) and not human subjects research (NHSR). Guidance is offered to new investigators for best practices in preparing for the ethical and responsible protection of human subjects in research and their data. Considerations for IRB policy and procedures, including suggestions for improving research protocol submissions for IRB review, are also offered.
Conserved missense variant pathogenicity and correlated phenotypes across paralogous genes
Bruenger, Tobias , Ivanuk, Alina, Cohen, Stacey , May, Patrick , Lal, Dennis , May, Patrick , Brünger, Tobias , Pérez‐Palma, Eduardo , Montanucci, Ludovica , Smith, Lacey A. , Parthasarathy, Shridhar , Helbig, Ingo , Nothnagel, Michael

Mayo Clinic

No container title available | November 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5434140/v1 Get It

Abstract Background The majority of missense variants in clinical genetic tests are classified as variants of uncertain significance. Prior research has shown that the deleterious effects and the subsequent molecular consequence of variants are often conserved among paralogous protein sequences within a gene family. Here, we systematically quantified on an exome-wide scale if the existence of pathogenic variants in paralogous genes at a conserved position could serve as evidence for the pathogenicity of a new variant. For the gene family of voltage-gated sodium channels where variants and expert-curated clinical phenotypes were available, we also assessed whether phenotype patterns of multiple disorders for each gene were also conserved across variant positions within the gene family. Methods We developed a framework that assesses the presence of pathogenic missense variants located in conserved residues across paralogous genes. We systematically mapped 2.5 million pathogenic and general population variants from the ClinVar, HGMD, and gnomAD databases onto a total of 9,990 genes and aligned them by gene families. We evaluated the quantity of classifiable amino acids by utilizing pathogenic variants identified in databases alone and then compared this assessment to the inclusion of paralogous pathogenic variants. We validated and quantified the evidence of conserved pathogenic paralogous variants in variant pathogenicity classification. Results Considering conserved pathogenic variants in paralogous genes, increased the number of classifiable variants 2.8-fold across the exome, compared to pathogenic variants in the gene of interest alone. The presence of a pathogenic variant in a paralogous gene is associated with a positive likelihood ratio of 8.32 for variant pathogenicity. The likelihood ratio was gene family-specific. Across ten genes encoding voltage-gated sodium channels and 22 expert-curated disorders, we identified cross-paralog correlated phenotypes based on 3D structure spatial position. For example, the established loss-of-function disorders SCN1A-associated Dravet syndrome, SCN2A-associated autism, SCN5A-associated Brugarda Syndrome, and SCN8A-associated neurodevelopmental disorder without seizures were correlated in their spatial variant position on structure. Finally, we show that phenotype integration in paralog variant selection improves variant classification. Conclusion Our results show that paralogous variants, in particular with phenotype information can enhance our understanding of variant effects.
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations
Smith, Katherine E. , Dasari, Surendra , Ranatunga, Wasantha , Rech, Karen L. , Ravindran, Aishwarya , McGarrah, Patrick W. , Ruan, Gordon , Zanwar, Saurabh , Sartori‐Valinotti, Julio C. , Snider, Jessica N., Abeykoon, Jithma P. , Smith, Katherine E R , Acosta-Medina, Aldo A, Rech, Karen , McGarrah, Patrick , Ruan, Gordon J , Zanwar, Saurabh S , LI, JENNY J., Sartori-Valinotti, Julio C., Witzig, T.E. , Goyal, Guarav , Go, Ronald S , Abeykoon, Jithma P , Ravindran, Aishwarya , Acosta‐Medina, Aldo A. , Young, Jason R. , Li, Jing , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

JCO Precision Oncology | November 22, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po-24-00471 | PMID 39576953 Get It

PURPOSE BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. METHODS We describe three patients with histiocytic disorders who have novel non-MAPK pathway alterations. These alterations were studied through genomic and in silico analyses when applicable, then treated with off-label medications rationally selected on the basis of genomic alterations. RESULTS Patient 1 had rapidly progressive ECD involving the CNS. A CSF1R in-frame deletion (p.S560_P566del) was identified, and in silico modeling predicted a gain-of-function mutation. This alteration was targeted with pexidartinib, which led to a clinical complete response (CR) within 2 months, and a partial response (PR) on imaging after 3 months. After 15 months, the disease became resistant to pexidartinib and transformed to histiocytic sarcoma. Patient 2 has skin-only involvement of a xanthogranuloma disorder. A KIF5B-FGFR1 fusion was identified on RNA sequencing and targeted with pemigatinib. At 24 months of follow-up, she remains in a clinical PR. Patient 3 has ECD involving the bone marrow, gastrointestinal tract, and subcutaneous tissues. A MEF2C-FLT3 fusion was identified and targeted with sorafenib. He achieved a clinical CR and radiographic PR within 3 months, which has continued for 30 months. CONCLUSION We report three patients with histiocytic disorders harboring novel alterations who had sustained responses to off-label kinase inhibitors specific to their histiocytic disorder. Pathogenic variants outside of the MAPK pathway, including variants of unknown significant, may be targeted with readily available small molecules.
American Society of Hematology: building a comprehensive minority recruitment and retention professional program
Rollins, Margo , Warsame, Rahma , Smith, Melody , Rouce, Rayne H. , Avalos, Belinda R. , Johnson, Cage S., López, José A. , Thompson, Alexis A. , Fanning, Lisa, Frustace, Patricia, Roche, Keelin F. , Havre, Nathalie van , Mack, Devon, Flowers, Christopher R. , Rollins, Margo R , Warsame, Rahma , Thompson, Alexis A , Terrell, Deirdra R , Smith, Melody , Molina, Arturo , Terrell, Deirdra R.

Mayo Clinic

Blood Advances | November 21, 2024 | Volume: 8 | Issue: 24 | Pages: 6237-6247

10.1182/bloodadvances.2024013519 | PMID 39570294 Get It

Abstract In 2003, the Institute of Medicine noted the need to improve workforce diversity. The American Society of Hematology (ASH) responded by developing the Minority Recruitment Initiative (MRI) to recruit diverse physicians/scientists into hematology. We evaluated the outcomes of the program. From 2004 to 2022, there were 405 awardees. Compared with national estimates, MRI awardees were less likely to discontinue their degree programs. MRI graduate student awardees had 0% attrition (97.5% confidence interval [CI], 10.6), whereas the national minority graduate student attrition was 36%. Medical student awardees had 2.2% (95% CI, 0.61-5.6) attrition, compared with the minority medical school attrition of 5.6%. Awardees were more likely than expected to pursue hematology-oncology (5.7% minority national estimate) because 14.4% (95% CI, 8.1-23.0) of medical student awardees and 88.5% (95% CI, 70.0-97.6) of early career awardees remain in the field. ASH has developed a successful program, but continued efforts are needed to advance equity in hematology.
Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation
Lorenz, Elizabeth C. , Smith, Byron H. , Wadei, Hani M. , Mour, Girish , Kennedy, Cassie C. , Schinstock, Carrie A. , Kremers, Walter K. , Cheville, Andrea , Hickson, LaTonya J. , Atkinson, Elizabeth J. , White, Thomas A. , Cheville, Andrea L , Rule, Andrew D , LeBrasseur, Nathan K , Smith, Byron , Hickson, LaTonya J , Schinstock, Carrie , Kennedy, Cassie C , Wadei, Hani M , Kremers, Walter K , Mour, Girish K , Rule, Andrew D. , LeBrasseur, Nathan K.

Mayo Clinic

Clinical Transplantation | November 20, 2024 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/ctr.70022 | PMID 39564682 Get It

ABSTRACTCellular senescence is a biological mechanism of aging and age‐related diseases. The aim of this study was to examine whether senescence biomarkers are associated with frailty and physical function trajectories in patients undergoing kidney transplantation (KT). We also discussed the relationship between senescence biomarkers and KT function. In this multicenter study, we prospectively assessed plasma levels of senescence biomarkers, frailty as measured by the Physical Frailty Phenotype, and physical function as measured by the Short Physical Performance Battery prior to KT. Frailty, physical function, and KT function were also measured 1 year after KT. Variable associations were assessed using Cox and relaxed least absolute shrinkage and selection operation regression. The cohort consisted of 197 participants (mean age 53 ± 13 years, 61.4% male, and 80.2% White race). Higher pre‐KT levels of macrophage‐derived chemokine (MDC/CCL22) and growth differentiation factor‐15 (GDF‐15) were independently associated with less improvement in frailty and/or physical function during the first year after KT. Higher pre‐KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP‐9 levels were independently associated with lower KT function one year after KT. Pre‐KT cellular senescence may contribute to frailty, physical function, and kidney function trajectories during the first year after KT.
Association Between Locomotor Muscle Quality and Cardiac Function During Exercise in Heart Failure with Preserved Ejection Fraction
Sharif, Salaheddin M. , Olson, Thomas P. , Smith, Joshua R. , Smith, Joshua R , Smith, Joshua R., Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | November 20, 2024 | Volume: 27 | Issue: 11 | Pages: 2521-2524

10.1002/ejhf.3528 | PMID 39563172 Get It

Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study
Sykora, Daniel , Olson, Nicole, Kim, B Michelle , Bratcher, Melanie, Elwazir, Mohamed Y. , Young, Kathleen A. , Ryan, Sami, Brodin, Michelle, Anderson, Jan, Saunders, Jeremiah, Ezzeddine, Omar Abou, Bois, John P. , Giudicessi, John R. , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Churchill, Robert , Elwazir, Mohamed , Young, Kathleen , Abou Ezzeddine, Omar, Giudicessi, J R , Cooper, Leslie T , Rosenbaum, Andrew N , AbouEzzeddine, Omar F , Kim, B Michelle , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | November 18, 2024 | Volume: 13 | Issue: 24 | Pages: No page available

10.1161/jaha.124.038965 | PMID 39556701 Get It

Background A multidisciplinary approach improves guideline‐directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist‐led medication therapy management (MTM) program for guideline‐directed medical therapy optimization (MTM versus non‐MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline‐directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event–free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I–II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P =0.83). At follow‐up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P <0.001; NMTM, 29.6 to 58.7; P <0.001) but was higher in MTM ( P =0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P =0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58–90.54]; P =0.002). Conclusions In this retrospective cohort study, a pharmacist‐led MTM program was associated with favorable guideline‐directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF.
A Novel Machine Learning Model to Predict Revision ACL Reconstruction Failure in the MARS Cohort
Group, MARS, Vasavada, Vrinda, Devana, Sai K. , Hame, Sharon L. , Jazrawi, Laith M. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Amendola, Annunziato, Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Dunn, Warren R. , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hannafin, Jo A., Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wright, Rick W. , York, James J. , Group, MARS, Vasavada, Kinjal , Moran, Jay T. , Lee, Chang Hee , Sherman, Orrin H. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 14, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241291920 | PMID 39555321 Get It

Background: As machine learning becomes increasingly utilized in orthopaedic clinical research, the application of machine learning methodology to cohort data from the Multicenter ACL Revision Study (MARS) presents a valuable opportunity to translate data into patient-specific insights. Purpose: To apply novel machine learning methodology to MARS cohort data to determine a predictive model of revision anterior cruciate ligament reconstruction (rACLR) graft failure and features most predictive of failure. Study Design: Cohort study; Level of evidence, 3. Methods: The authors prospectively recruited patients undergoing rACLR from the MARS cohort and obtained preoperative radiographs, surgeon-reported intraoperative findings, and 2- and 6-year follow-up data on patient-reported outcomes, additional surgeries, and graft failure. Machine learning models including logistic regression (LR), XGBoost, gradient boosting (GB), random forest (RF), and a validated ensemble algorithm (AutoPrognosis) were built to predict graft failure by 6 years postoperatively. Validated performance metrics and feature importance measures were used to evaluate model performance. Results: The cohort included 960 patients who completed 6-year follow-up, with 5.7% (n = 55) experiencing graft failure. AutoPrognosis demonstrated the highest discriminative power (model area under the receiver operating characteristic curve: AutoPrognosis, 0.703; RF, 0.618; GB, 0.660; XGBoost, 0.680; LR, 0.592), with well-calibrated scores (model Brier score: AutoPrognosis, 0.053; RF, 0.054; GB, 0.057; XGBoost, 0.058; LR, 0.111). The most important features for AutoPrognosis model performance were prior compromised femoral and tibial tunnels (placement and size) and allograft graft type used in current rACLR. Conclusion: The present study demonstrated the ability of the novel AutoPrognosis machine learning model to best predict the risk of graft failure in patients undergoing rACLR at 6 years postoperatively with moderate predictive ability. Femoral and tibial tunnel size and position in prior ACLR and allograft use in current rACLR were all risk factors for rACLR failure in the context of the AutoPrognosis model. This study describes a unique model that can be externally validated with larger data sets and contribute toward the creation of a robust rACLR bedside risk calculator in future studies. Registration: NCT00625885 (ClinicalTrials.gov identifier).
Abstract 4144060: Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest
Swain, William H , Garmany, Ramin , Ackerman, Michael J. , Giudicessi, John R. , Castrichini, Matteo , Bos, J. Martijn , Neves, Raquel , Garmany, Ramin

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4144060 Get It

Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart disease characterized by proclivity for ventricular arrhythmias and systolic dysfunction. Rarely, sudden cardiac arrest (SCA) is the presenting event in ACM. These individuals may have concealed disease with no appreciable structural manifestations on imaging. Aims: To determine the prevalence, clinical features, and outcomes of patients with genotype-positive ACM who presented with a sentinel SCA. Methods: In this retrospective study, 445 genotype-positive ACM patients evaluated from 1/2015-4/2024 were analyzed to identify those whose initial presentation was SCA. Pertinent demographic, clinical, genetic, and outcome data were extracted from the electronic medical record. Structural manifestations were defined by having one of the following on baseline TTE: EF < 50%, LVEDV >56 mL (male) or >51 mL (female), or regional RV akinesia, dyskinesia, or aneurysm. Categorical variables are presented as number (%), and continuous variables as median (IQR). Statistical analysis was done using Fisher’s exact test (categorical), t-test (continuous), and Logrank test (survival). Patients were censored at time of transplant, death, or last followup. Results: Overall, 14/445 (3%) ACM patients presented with sentinel SCA [71% male; median age at SCA 39 (IQR 30-46)]. The most common genetic substrates were DSP -encoded desmoplakin (n=4; 29%), LMNA -encoded lamin A/C (n=3; 21%), and PKP2 -encoded plakophilin-2 (n=3; 21%). During a median followup of 8.4 years, 12 (86%) experienced appropriate ICD shocks, 8 (57%) required catheter ablation for ventricular arrhythmias, 6 (42%) underwent transplant, and 2 (14%) died of cardiac causes. Notably, 5 (35%) patients did not have evidence of structural disease during baseline evaluation. Compared to those with structural disease, this group was younger [median age 28 (IQR 21-29) vs 45 (IQR 41-48), p = 0.002] and less likely to undergo transplant [0 (0%) vs 6 (42%), p = 0.03]. Conclusions: Sentinel SCA is a rare presentation in ACM and may precede overt structural cardiac changes in a subset of younger patients. This population remains at increased risk for recurrent ventricular arrhythmias and often require advanced therapies.